Literature DB >> 28639996

Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa?

Guinevere Q Lee1, Suzanne McCluskey, Yap Boum, Peter W Hunt, Jeffrey N Martin, David R Bangsberg, Xiaojiang Gao, P Richard Harrigan, Jessica E Haberer, Mark J Siedner.   

Abstract

Despite a poor toxicity profile, zidovudine supersedes abacavir (ABC) as an alternative first-line agent in most international treatment guidelines because of concerns about HLA-B*57:01-related ABC-hypersensitivity. We detected one case of HLA-B*57:01 carriage among 513 HIV-infected individuals in Uganda, which, in combination with previous reports, supports the safety of ABC in the region.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28639996      PMCID： PMC5597467          DOI： 10.1097/QAI.0000000000001487

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


  40 in total

1.  Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.

Authors:  S A Mallal; M John; C B Moore; I R James; E J McKinnon
Journal:  AIDS       Date:  2000-07-07       Impact factor: 4.177

2.  Frequencies of immune hypersensitivity reaction-associated HLA class I alleles in healthy South African Indian and mixed ancestry populations determined by a novel real-time PCR assay.

Authors:  S Loubser; M Paximadis; N Gentle; A Puren; C M Gray; C T Tiemessen
Journal:  Tissue Antigens       Date:  2014-08-25

3.  No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.

Authors:  Heather J Ribaudo; Constance A Benson; Yu Zheng; Susan L Koletar; Ann C Collier; Judith J Lok; Marlene Smurzynski; Ronald J Bosch; Barbara Bastow; Jeffrey T Schouten
Journal:  Clin Infect Dis       Date:  2011-04-01       Impact factor: 9.079

4.  Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

Authors:  Joel E Gallant; Edwin DeJesus; José R Arribas; Anton L Pozniak; Brian Gazzard; Rafael E Campo; Biao Lu; Damian McColl; Steven Chuck; Jeffrey Enejosa; John J Toole; Andrew K Cheng
Journal:  N Engl J Med       Date:  2006-01-19       Impact factor: 91.245

5.  Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.

Authors:  Sylvie Lang; Murielle Mary-Krause; Laurent Cotte; Jacques Gilquin; Marialuisa Partisani; Anne Simon; Franck Boccara; Dominique Costagliola
Journal:  Arch Intern Med       Date:  2010-07-26

6.  The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy.

Authors:  Helen Byakwaga; Yap Boum; Yong Huang; Conrad Muzoora; Annet Kembabazi; Sheri D Weiser; John Bennett; Huyen Cao; Jessica E Haberer; Steven G Deeks; David R Bangsberg; Joseph M McCune; Jeffrey N Martin; Peter W Hunt
Journal:  J Infect Dis       Date:  2014-02-28       Impact factor: 5.226

7.  Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.

Authors:  Juan Berenguer; Juan González; Esteban Ribera; Pere Domingo; Jesús Santos; Pilar Miralles; M Angels Ribas; Víctor Asensi; Juan Luis Gimeno; José Antonio Pérez-Molina; José Alberto Terrón; Juan Miguel Santamaría; Enric Pedrol
Journal:  Clin Infect Dis       Date:  2008-10-15       Impact factor: 9.079

Review 8.  AZT: an old drug with new perspectives.

Authors:  Gabriele D'Andrea; Fabrizia Brisdelli; Argante Bozzi
Journal:  Curr Clin Pharmacol       Date:  2008-01

9.  Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.

Authors:  Edwin DeJesus; Gisela Herrera; Eugenio Teofilo; Jan Gerstoft; Carlos Beltran Buendia; J David Brand; Cynthia H Brothers; Jaime Hernandez; Steve A Castillo; Tab Bonny; E Randall Lanier; Trevor R Scott
Journal:  Clin Infect Dis       Date:  2004-09-10       Impact factor: 9.079

10.  Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.

Authors:  Paula Munderi; Wendy B Snowden; Ann Sarah Walker; Cissy Kityo; Michael Mosteller; Geoffrey Kabuye; Navdeep K Thoofer; Francis Ssali; Charles F Gilks; Arlene R Hughes
Journal:  Trop Med Int Health       Date:  2010-11-23       Impact factor: 2.622
View more
  1 in total

1.  Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa.

Authors:  Didier K Ekouevi; Serge P Eholie; Malewe Kolou; Armel Poda; Zelica Diallo; Esther Konou; Tatiana Dokpomiwa; Jacques Zoungrana; Mounerou Salou; Lionèle Mba-Tchounga; André Bigot; Abdoul-Salam Ouedraogo; Marielle Bouyout-Akoutet
Journal:  BMC Immunol       Date:  2021-07-22       Impact factor: 3.615
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.